SmallCapStockTips

SmallCapStockTips

Posts by SmallCapStockTips

CNOOC Limited Announces Buzios7 Project Commences Production

CNOOC Limited Announces Buzios7 Project Commences Production

February 17, 2025

Funding Secured to Advance the Adina Lithium Project and Extend the Renard Option

Funding Secured to Advance the Adina Lithium Project and Extend the Renard Option

February 17, 2025

ZICC: The Thriving Countryside

Travel & Hospitality

ZICC: The Thriving Countryside

February 17, 2025

Fosun Pharma Deeply Embraces AI, Self-developed PharmAID Decision Intelligence Platform Boosts Efficient Innovation

Fosun Pharma Deeply Embraces AI, Self-developed PharmAID Decision Intelligence Platform Boosts Efficient Innovation

February 17, 2025

Stryker launches ProCeed hospital bed

Stryker launches ProCeed hospital bed

February 17, 2025

CTCI Ranks Top 1% for Three Consecutive Years in S&P Global’s Sustainability Yearbook

CTCI Ranks Top 1% for Three Consecutive Years in S&P Global’s Sustainability Yearbook

February 17, 2025

Artificial Intelligence (AI) in Games Market to Grow by USD 27.47 Billion from 2025 to 2029, Driven by AR and VR Game Adoption, Report on AI Impact on Market Trends – Technavio

Artificial Intelligence (AI) in Games Market to Grow by USD 27.47 Billion from 2025 to 2029, Driven by AR and VR Game Adoption, Report on AI Impact on Market Trends – Technavio

February 17, 2025

DeriW: A Zero-Gas Trading Platform to Debut With Testnet at Consensus Hong Kong 2025

DeriW: A Zero-Gas Trading Platform to Debut With Testnet at Consensus Hong Kong 2025

February 17, 2025

FDA GRANTS FAST TRACK DESIGNATION TO PLEOPHARMA, INC’s INVESTIGATIONAL NEW DRUG, PP-01, FOR THE MITIGATION OF CANNABIS WITHDRAWAL SYMPTOMS IN PATIENTS WITH CANNABIS USE DISORDER: A POTENTIAL FIRST IN CLASS TREATMENT

FDA GRANTS FAST TRACK DESIGNATION TO PLEOPHARMA, INC’s INVESTIGATIONAL NEW DRUG, PP-01, FOR THE MITIGATION OF CANNABIS WITHDRAWAL SYMPTOMS IN PATIENTS WITH CANNABIS USE DISORDER: A POTENTIAL FIRST IN CLASS TREATMENT

February 17, 2025

Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer

Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer

February 17, 2025

« 1 … 40 41 42 43 44 … 94 »